SBIR/STTR Research Award
TAS::75 0893::TAS RAPID QUANTITATIVE POINT OF CARE TEST FOR NICOTINE METABOLITE RATIO, SILOAM BIOSCIENCES, INC. CINCINNATI, OH
Award amount
$997,254Program and phase
SBIR · Phase IIAward year
2011Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SILOAM BIOSCIENCES
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- NIDA
Research abstract
Recent clinical research has established that this ratio is indicative of the activity of the CYP2A6 enzyme that metabolises nicotine. Nicotine is metabolized to COT and then to 3HC. People with high activity of this enzyme, clear nicotine faster and henceneed more nicotine to maintain the addiction. To-date the 3HC/COT ratio could only be determined by specialized measurement techniques such as Liquid-Chromatography/Mass Spectrometry. Although accurate, these tests are expensive and take 2-5 days to deliver results. Smoking is the leading cause of cancer related deaths, and is attributable cause for almost 400,000 deaths per year in the US> The POCT for nicotine metabolites can help in increasing smoking cessation rates and directly contribute to reduced mortality/healthcare burden.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)